Polaryx Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Polaryx Therapeutics, Inc. (PLYX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $243.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Polaryx Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$152.00K, a 317.14% decline year-over-year.
- Polaryx Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $395.00K, a 9775.00% increase year-over-year.
- Polaryx Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was $70.00K.
- Polaryx Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-03-31 was $4.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month |
|---|---|---|
| 2026-06-30 | -$152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $243.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $395.00K 10-Q · filed 2026-05-15 | |
| 2025-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $74.00K 10-Q · filed 2026-08-13 |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |